An observational study in Dengue, sponsored by Fundacion GESICA. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-28.
Sponsored by Fundacion GESICA · Observational
Among all arboviruses, Dengue (DEN) is the vector borne disease with the highest burden worldwide. Around 390 million infections per year are estimated, of which around 96 million are clinically apparent.
Since its re-emergence in 1998 in Argentina, DEN has shown an epidemic behavior affecting mainly the northern and central regions in which the circulation of serotypes has been heterogeneous. The last significant outbreak was registered between the end of 2019 and the beginning of 2020..
Vaccine development for DEN prevention has been a long and challenging journey. The only vaccine that has reached registration to date is a recombinant attenuated tetravalent vaccine (Dengvaxia, Sanofi Pasteur) showing an efficacy against virological confirmed DEN infection of 36.6% (4.2-61.4) in seronegative subjects at baseline and 77.9% (65.1-86.0) in seropositive. However, this vaccine has not been pre qualified by the World Health Organization. New dengue vaccines are in advanced stages of development worldwide. At least three vaccines are in advanced stages of development including one produced by Takeda, the Butantan Institute and the Merck, Sharp \& Dohme development.
The implementation of a vaccination strategy in Argentina could be a health-relevant approach. However, the best way to implement this requires prior information describing and investigating numerous aspects of vaccination including acceptability.
A systematic review of two acceptability surveys showed an acceptability of 77% to 86% but in countries with endemic DEN at time of the surveys.
It is possible that in Argentina, the introduction to the regular calendar, for use in specific regions with a high and periodic burden of disease, of highly effective and safe DEN vaccines will be considered. However, to our knowledge, we do not have available evidence of the potential acceptability of these vaccines.
The main objectives of this research will be:
To evaluate the acceptability of a DEN vaccine in potential target populations in regions of high burden of disease in Argentina.
Describe main determinants of and barriers to DEN vaccine acceptability in regions of high burden of disease in Argentina.
Identify information and intervention needs to design and implement communication strategies that have a positive impact on the acceptability of a DEN vaccine.
279 studies on the registry are indexed under Dengue; 45 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 595 across 78 observational studies indexed under Dengue.
Browse Dengue studies →Fundacion GESICA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals aged 18 years or older, residing in one of the three districts with the highest burden of NDD in Argentina who provide written informed consent to participate in the survey.
Exclusion Criteria:
Proportion of subjects who express acceptability to the DEN vaccine.
Time frame: Baseline (time 0)
Proportion of subjects who express acceptability to the DEN vaccine.
Time frame: At 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion GESICA